help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology, doi:10.1210/me.2007-0437
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faivre, E. J.
Right arrow Articles by Lange, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faivre, E. J.
Right arrow Articles by Lange, C. A.
Molecular Endocrinology 22 (4): 823-837
Copyright © 2008 by The Endocrine Society

Progesterone Receptor Rapid Signaling Mediates Serine 345 Phosphorylation and Tethering to Specificity Protein 1 Transcription Factors

Emily J. Faivre, Andrea R. Daniel, Christopher J. Hillard and Carol A. Lange

Departments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455

Address all correspondence and requests for reprints to: Carol A. Lange, Ph.D., University of Minnesota Cancer Center, 420 Delaware Street SE, MMC 806, Minneapolis, Minnesota 55455. E-mail: Lange047{at}umn.edu.

Human progesterone receptors (PR) rapidly activate cytosolic signaling pathways, in addition to their classical function as ligand-activated transcription factors. Using ER+/PR-B+ T47D breast cancer cells, we probed the role of progestin-stimulated rapid PR signaling in the transcriptional regulation of target genes involved in breast cancer cell proliferation. Epidermal growth factor receptor (EGFR) was rapidly activated after a 10-min treatment with R5020. Progestin induced EGFR-, c-Src-, and MAPK-dependent phosphorylation of PR-B on the MAPK consensus site, Ser345. Ser345-phosphorylated PR-B receptors strongly associated with specificity protein 1 (Sp1) transcription factors to regulate PR cell cycle (p21) and growth-promoting (EGFR) target genes whose promoters lack canonical progesterone response element sequences. Inhibitors of EGFR, c-Src, or MAPK activities blocked PR tethering to Sp1 and progestin-stimulated S-phase entry. Mutant PR-B receptors defective for c-Src binding (mPro) were not phosphorylated on Ser345 in response to progestin and failed to interact with Sp1. Hormone-induced complexes containing Sp1 and wild-type PR-B, but not S345A or mPro PR-B, were recruited to Sp1 sites within the endogenous p21 promoter. Progestin-induced S-phase entry was attenuated in T47D cells containing wild-type PR-B and treated with EGFR, c-Src, or MAPK kinase inhibitors or in T47D cells stably expressing mPro or mutant DNA-binding domain PR-B. In sum, rapid progestin-activated PR signaling leads to PR Ser345 phosphorylation and tethering to Sp1. These events are critical for progestin-stimulated regulation of Sp1 target genes and breast cancer cell proliferation. Our data demonstrate the therapeutic potential for PR-targeted breast cancer treatment by exploiting multiple nodes along the PR signaling pathway, including PR-B, EGFR, c-Src, MAPK, or Sp1.

NURSA Molecule Pages Link:

Nuclear Receptors:   PR
Ligands:   Progesterone  |  RU486  |  R5020



This article has been cited by other articles:


Home page
EndocrinologyHome page
J. P. Lydon and D. P. Edwards
Finally! A Model for Progesterone Receptor Action in Normal Human Breast
Endocrinology, July 1, 2009; 150(7): 2988 - 2990.
[Full Text] [PDF]


Home page
Endocr Relat CancerHome page
G. E Dressing, C. R Hagan, T. P Knutson, A. R Daniel, and C. A Lange
Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models
Endocr. Relat. Cancer, June 1, 2009; 16(2): 351 - 361.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
I. Quiles, L. Millan-Arino, A. Subtil-Rodriguez, B. Minana, N. Spinedi, C. Ballare, M. Beato, and A. Jordan
Mutational Analysis of Progesterone Receptor Functional Domains in Stable Cell Lines Delineates Sets of Genes Regulated by Different Mechanisms
Mol. Endocrinol., June 1, 2009; 23(6): 809 - 826.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. J. Proietti, C. Rosemblit, W. Beguelin, M. A. Rivas, M. C. Diaz Flaque, E. H. Charreau, R. Schillaci, and P. V. Elizalde
Activation of Stat3 by Heregulin/ErbB-2 through the Co-Option of Progesterone Receptor Signaling Drives Breast Cancer Growth
Mol. Cell. Biol., March 1, 2009; 29(5): 1249 - 1265.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society